drugset / Trial / NCT00975104
AMG 745 in Subjects With Age-associated Muscle Loss
RandomizedParallel-groupDouble-blindTreatment
Summary
Randomized, Double-blind, Placebo-controlled Dose Ranging Study to Evaluate the Safety and Efficacy of AMG 745 in Age-associated Muscle Loss
Timeline
- Start
- 2010-04
- Primary completion
- 2011-05
- Completion
- 2011-08
Outcome
Outcome not reported
Stopped: “Amgen has chosen at this time not to continue with AMG 745 study 20080733”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AMG 745 | Unknown | 0.3 mg/kg | Intravenous |
| Subject | AMG 745 | Unknown | 1 mg/kg | Intravenous |
| Subject | AMG 745 | Unknown | 3 mg/kg | Intravenous |